The cardiology societies signed off on ASC ablation — and that's the part that de-risks the build

The newsworthy thing about cardiac ablation moving into ambulatory surgery centers is not that CMS added the codes — that was reported in the CY2026 final rule and is already being built against. The underreported part is that the field’s own physician societies put their endorsement on the federal record first. On July 29, 2025, the Heart Rhythm Society and its advocacy arm, Heart Rhythm Advocates, told CMS in a comment letter that “the evidence from published experiences strongly supports the safety, feasibility, and efficacy of performing cardiac ablations and related ablation procedures in ASCs with same day discharge in appropriately selected patients.”

For an operator, that sentence is worth more than the rate. It is the document you hand a hospital medical-staff committee or a commercial payer’s medical director when they ask whether moving electrophysiology out of the hospital is reckless. The specialty that owns the procedure already answered, in writing, to the regulator.

The endorsement is the de-risking event, not the coverage

New ASC service lines rarely die on the capital question. They die earlier, in credentialing and payer review, when someone with a veto says the procedure belongs in a hospital. Ablation has carried exactly that presumption for two decades — Heart Rhythm Advocates notes Medicare “allowed EP ablations only in hospital outpatient departments, largely due to concerns about complexity and whether ASCs could support these procedures safely.” An endorsement from HRS removes the cleanest version of that objection.

The societies did not stop at the comment letter. The HRS/ACC writing committee that produced the accompanying scientific statement framed the move as conditional, not blanket. Committee co-chair Amit Shanker, MD, told TCTMD on November 25, 2025 that “these ablation procedures can be performed in appropriately selected patients” in ASCs — with TCTMD’s report noting that patient selection is one of the key aspects of the document — and that the statement “calls for collaborative, data-driven policies that expand access and efficiency while safeguarding system-wide capacity for complex and emergent cardiac care.” That hedged language is itself useful to an operator: it gives a credentialing committee a defensible standard (“appropriately selected patients”) rather than an all-or-nothing fight.

In its comment letter, HRS and HRA told CMS the inclusion would “help to greatly improve beneficiary access, while reducing cost for both patients and the healthcare system” — the access-and-cost argument that payers, the other gatekeeper, are built to respond to.

What CMS actually finalized, recomputed from the rate tables

The endorsement matters because of what it unlocks: a high-dollar line. CMS finalized six cardiac ablation procedure codes plus seven additional EP procedure codes — requested through public comment — onto the ASC Covered Procedures List, effective January 1, 2026. The codes and their finalized ASC rates, drawn from the CY2026 OPPS Final Notice Addenda AA and BB as compiled in Boston Scientific’s public summary of the final rule:

• 93650 — AV node ablation: $5,943 (ASC status indicator J8, device-intensive)
• 93653 — SVT ablation: $19,176
• 93654 — ventricular tachycardia ablation: $19,482
• 93656 — atrial fibrillation ablation by pulmonary vein isolation: $20,256
• 93655 / 93657 — add-on ablation codes: status N1, packaged, no separate ASC payment

Two things in that table matter for a build model. First, the add-on codes (93655, 93657) pay nothing separately in the ASC — they are packaged — so a case-mix model that assumes incremental revenue for a second lesion set is wrong. The revenue is the primary code. Second, these are device-intensive (J8) procedures: the payment is built around the cost of the catheter and mapping consumables, which is also why the per-case capital and supply exposure is high.

The setting spread is the policy driver beneath the rate

The rate alone does not explain why volume would move. The spread does. For the flagship code, atrial-fibrillation ablation, the ASC pays $20,256; the matched hospital outpatient line — APC 5213, “Level 3 Electrophysiologic Procedures (AF, VT, or SVT Ablation)” — pays $26,704 for CY2026 in the same Boston Scientific compilation of CMS Addendum A. That is a $6,448 gap, or about 24% lower in the ASC. For SVT ablation (93653) the ASC’s $19,176 runs roughly $7,500, or 28%, under the same HOPD APC.

That gap is the entire mechanism. It is what lets a commercial payer steer an ablation to the ASC and book the savings, and it is what a Medicare Advantage plan models when it builds a site-of-service policy. The society endorsement clears the clinical objection; the 24-to-28% setting spread supplies the financial motive for the payer to push the case through the door the endorsement opened. Note the asymmetry CMS baked in: hospital outpatient ablation rates rose — APC 5213 is up 9% for 2026 — even as the new ASC option undercuts them, so the spread is structural, not a one-year artifact.

Capex, CON and staffing still decide who builds

None of this makes an EP ASC easy to stand up, and the gating factors are different in kind from the ones the endorsement solved. The peer-reviewed literature is blunt about it. Reviewing the CMS decision in the Journal of Innovations in Cardiac Rhythm Management (Aryana A, Swarup V; 2026;17(1):6557–6560), the authors flag that “state regulations vary widely, and certificate-of-need rules may limit expansion,” and that staffing means “nurses, technicians, and anesthesia teams with EP-specific expertise and familiarity with same-day discharge workflows” — a labor pool that does not transfer from a general multispecialty ASC. On the capital side, industry coverage notes that establishing an EP-capable ASC “can require millions of dollars in startup capital,” pushing physicians toward hospital, management-company or private-equity partners to finance and run it.

So the barriers re-sort. The endorsement and the rate handle the demand side — credentialing, payer acceptance, a five-figure payment per case. Certificate-of-need, capital, and a thin bench of EP-trained ASC staff handle the supply side, and those are slower to move. An operator in a CON state without an electrophysiologist already in the partnership is not closer to an EP line because of this rule; an operator in a no-CON state with an EP physician-owner and access to capital is meaningfully closer, and now has the society’s signature to cite when the medical-staff committee asks why.

What to watch

The first real test of the rate is the CY2027 proposed rule, expected around July 2026, which will set the second-year ASC payment for these codes and show whether CMS holds the device-intensive treatment that makes the math work. Watch state CON dockets for de novo cardiac and EP centers — that is where the supply-side gate is litigated case by case. And watch whether commercial and Medicare Advantage payers translate the 24-to-28% setting spread into explicit site-of-service policies; the endorsement gave them the clinical cover to do it.